In North America and Europe approximately 940 million people are at risk of bioterrorism agents. According to the World Health Organization, its committee of experts’ estimates that an aircraft release of 50 kg of anthrax spores over an urban developed population of 5 million would result in about 250,000 deaths and an additional 125,000 would be severely incapacitated.
- Anthrax: Greffex produced the anthrax vaccine GreANX based on its GreVAX Universal Platform. This anthrax vaccine has successfully undergone preclinical testing.
- Plague: Greffex has been constructing the GrePla candidate vaccine as a single target vaccine that can be combined with GreANX for immunization.